Trial Profile

Second phase 2/3 placebo-controlled trial of PBI-4050 in Idiopathic Pulmonary Fibrosis patients who have failed to tolerate nintedanib or pirfenidone.

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jul 2022 According to Liminal BioSciences media release, the company has discontinued development of fezagepras based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The recommendation to stop the development program for fezagepras was not based on safety concerns.
21 Jul 2022 Status changed from planning to discontinued, according to a Liminal BioSciences media release.
10 May 2017 According to a ProMetic Life Sciences media release, the company scheduled to initiate this trial in second quarter of 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com